3 results on '"Ganoczy, Dara"'
Search Results
2. Opioid dose and risk of suicide.
- Author
-
Ilgen, Mark A., Bohnert, Amy S. B., Ganoczy, Dara, Bair, Matthew J., McCarthy, John F., and Blow, Frederic C.
- Subjects
- *
SUICIDE risk factors , *DRUG therapy , *OPIOIDS , *CHRONIC pain treatment , *DRUG dosage , *SEVERITY of illness index , *MEDICAL research , *CHRONIC pain & psychology , *SUICIDE & psychology , *THERAPEUTIC use of narcotics , *ANALGESICS , *CHRONIC pain , *COMPARATIVE studies , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *MORTALITY , *NARCOTICS , *HEALTH outcome assessment , *RESEARCH , *RESEARCH funding , *SUBSTANCE abuse , *EVALUATION research - Abstract
Chronic pain is associated with increased risk of suicide, and opioids are commonly used to treat moderate to severe pain. However, the association between opioid dose and suicide mortality has not been examined closely. This retrospective data analysis described the risk of suicide associated with differing prescribed opioid doses. Data were from Veterans Affairs health care system treatment records and the National Death Index. Records analyzed were those of Veterans Affairs patients with chronic pain receiving opioids in fiscal years 2004 to 2005 (N = 123,946). Primary predictors were maximum prescribed morphine-equivalent daily opioid dose and opioid fill type. The main outcome measured was suicide death, by any mechanism, and intentional overdose death during 2004 to 2009. Controlling for demographic and clinical characteristics, higher prescribed opioid doses were associated with elevated suicide risk. Compared with those receiving ≤20 milligrams/day (mg/d), hazard ratios were 1.48 (95% confidence intervals [CI], 1.25-1.75) for 20 to <50 mg/d, 1.69 (95% CI, 1.33-2.14) for 50 to <100 mg/d, and 2.15 (95% CI, 1.64-2.81) for 100+ mg/d. The magnitude of association between opioid dose and suicide by intentional overdose was not substantially different from that observed for the overall measure of suicide mortality. Risk of suicide mortality was greater among individuals receiving higher doses of opioids, and treatment providers may want to view high opioid dose as a marker of elevated risk for suicide. Additional research is needed on opioid use, pain treatment, and suicide. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Impact of the Opioid Safety Initiative on opioid-related prescribing in veterans.
- Author
-
Lin, Lewei A., Bohnert, Amy S. B., Kerns, Robert D., Clay, Michael A., Ganoczy, Dara, and Ilgen, Mark A.
- Subjects
- *
MEDICATION safety , *DRUG prescribing , *OPIOIDS , *VETERANS' health , *CONFIDENCE intervals , *BENZODIAZEPINES , *THERAPEUTIC use of narcotics , *TRANQUILIZING drugs , *ANALGESICS , *CHRONIC pain , *DRUGS , *VETERANS , *NARCOTICS , *SUBSTANCE abuse , *VETERANS' hospitals , *RETROSPECTIVE studies - Abstract
The Veterans Health Administration (VHA) designed the Opioid Safety Initiative (OSI) to help decrease opioid prescribing practices associated with adverse outcomes. Key components included disseminating a dashboard tool that aggregates electronic medical record data to audit real-time opioid-related prescribing and identifying a clinical leader at each facility to implement the tool and promote safer prescribing. This study examines changes associated with OSI implementation in October 2013 among all adult VHA patients who filled outpatient opioid prescriptions. Interrupted time series analyses controlled for baseline trends and examined data from October 2012 to September 2014 to determine the changes after OSI implementation in prescribing of high-dosage opioid regimens (total daily dosages >100 morphine equivalents [MEQ] and >200 MEQ) and concurrent benzodiazepines. Across VHA facilities nationwide, there was a decreasing trend in high-dosage opioid prescribing with 55,722 patients receiving daily opioid dosages >100 MEQ in October 2012, which decreased to 46,780 in September 2014 (16% reduction). The OSI was associated with an additional decrease, compared to pre-OSI trends, of 331 patients per month (95% confidence interval [CI] -378 to -284) receiving opioids >100 MEQ, a decrease of 164 patients per month (95% CI -186 to -142) receiving opioids >200 MEQ, and a decrease of 781 patients per month (95% CI -969 to -593) receiving concurrent benzodiazepines. Implementation of a national health care system-wide initiative was associated with reductions in outpatient prescribing of risky opioid regimens. These findings provide evidence for the potential utility of large-scale interventions to promote safer opioid prescribing. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.